Progressive shares fall as Q3 earnings, revenue miss expectations
ZyVersa Therapeutics, Inc. (OTCQB:ZVSA) announced Thursday that the Nasdaq Stock Market will formally delist the company’s common stock. According to a press release statement and a recent SEC filing, Nasdaq plans to file a Form 25 with the Securities and Exchange Commission to complete the delisting process. The delisting will become effective ten days after the form is filed.
ZyVersa’s common stock was suspended from trading on the Nasdaq Capital Market on July 17, 2025, after the company failed to regain compliance with the minimum bid price requirements under Nasdaq Listing Rule 5550(a)(2). Since July 28, 2025, ZyVersa’s shares have been trading on the OTCQB Venture Market under the symbol ZVSA.
The company reported that its common stock will continue to trade on the OTCQB without disruption following the delisting from Nasdaq.
This information is based on a press release statement and ZyVersa Therapeutics’ Form 8-K filing with the SEC.
In other recent news, ZyVersa Therapeutics has initiated a phase 2a clinical trial for its Cholesterol Efflux Mediator, VAR 200, targeting diabetic kidney disease. The company also announced that it has secured $12 million in financing to advance its research and development programs for kidney and inflammatory diseases. This financing includes a $2 million warrant inducement transaction and a Share Purchase Agreement for up to $10 million with Williamsburg Venture Holdings. In a separate development, ZyVersa received FDA authorization for Emergency Compassionate Use of VAR 200 in a patient with ApoCII amyloidosis, an ultra-rare kidney condition.
Additionally, ZyVersa’s common stock has been approved for quotation on the OTCQB Venture Market, with trading expected to begin under its current symbol. However, the company will be delisted from the Nasdaq Capital Market following a denied appeal regarding noncompliance with the minimum bid price requirement. This decision means its securities will be suspended from trading on the Nasdaq. These developments highlight ZyVersa’s ongoing efforts in both clinical advancements and financial maneuvers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.